79 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 THERMO FISHER SCIENTIFIC the infrastructure supporting them. Facilities, analytical capabilities, and manufacturing technologies must adapt as programs scale or as molecules behave differently than expected during GMP scale manufacturing. When those capabilities are not aligned with program needs, development timelines can stretch while teams work through adjustments. Global supply chain development adds another layer of complexity. Clinical trials increasingly span multiple regions, and manufacturing or supply chain networks often extend across geographies. Maintaining consistent quality oversight and supply continuity across those environments requires systems that can operate reliably at scale. These challenges are familiar to anyone involved in clinical development. What has shifted is the degree to which they influence the trajectory of programs. As complexity increases, execution discipline plays a larger role in determining whether development progresses smoothly or stalls during critical transitions. Conditions that help complex programs move forward Across the industry, programs that maintain momentum despite growing complexity tend to share several operational characteristics: scalable quality systems, flexible development and manufacturing environments, sustained investment in infrastructure, and closer coordination across development and supply. Quality systems designed to scale Quality oversight has always been foundational to pharmaceutical development and manufacturing. What has evolved is both the scale and the role that quality plays as development programs expand across technologies, sites, and geographies. Today, quality functions less as a set of checkpoints and more as a operational network discipline and culture that supports consistent execution across the development lifecycle. As programs move between facilities, technologies, and stages of development, quality processes and culture are critical to maintain alignment between development work, manufacturing processes, and regulatory expectations. Just as important, they reinforce a shared understanding across teams that quality is not confined to a single function. It is embedded in how development and manufacturing work is carried out every day. Development programs now frequently involve multiple sites, technologies, and regulatory jurisdictions. Programs may move between facilities as volumes grow or as specialized capabilities become necessary. In these settings, quality culture and practices must support consistent execution while still allowing the flexibility required during development. When quality practices are designed with program scale and advancement in mind, organizations can maintain continuity as work expands across sites or transitions toward commercial manufacturing. That continuity reduces risk during moments that historically introduce disruption, such as technology transfer or process scale-up. Quality, in this context, becomes less about oversight at individual facilities and more about creating stable conditions across an entire network Operational flexibility as programs evolve Few development programs proceed exactly as planned. Clinical data can influence formulation and technology transfer strategies. Manufacturing processes may change as scale increases. Regulatory or geographic considerations may alter development pathways. In many cases, these adjustments occur while programs are already advancing toward clinical milestones. The ability to adapt and absorb change without restarting foundational work has therefore become an important operational advantage. Flexibility often depends on access to development and manufacturing environments that can accommodate a range of program requirements. Development teams may need to adjust formulation and process approaches as new data emerges, scale manufacturing processes while maintaining product performance, or expand supply strategies as clinical programs move into additional regions. Organizations that maintain diverse development and manufacturing capabilities are often better positioned to adapt when these shifts occur. Access to multiple process technologies, flexible manufacturing capacity, and development teams experienced in navigating technical change can help programs adjust without losing momentum. This flexibility allows development teams to adapt as programs evolve while maintaining continuity across development, manufacturing, and supply.
RkJQdWJsaXNoZXIy MjY2OTA4MA==